Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

MENDEL: AMG 145 Monotherapy for Hypercholesterolemia

LAPLACE-TIMI 57: AMG 145 Combined With Statin for Hypercholesterolemia

GAUSS: AMG 145 in Statin Intolerance

Dosing and Administration

GLAGOV Trial

JUPITER: Attaining an LDL-C Level < 50 mg/dL

Phase 3 Trials

Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

Genetic defects identified in FH

ENHANCESimvastatin/Ezetimibe in FH

OSLER Study: Long-term AMG 145 Therapy

Safety of AMG 145

How low is too low?

Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

Genetics: PCSK9

Loss-of-Function PCSK9 Mutation:Distribution of LDL-C Levels

Diagnosis of FH

Determinants of PCSK9 Efficacy

Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

Timelines of Lipid-Lowering Agents

Dallas Heart Study: Lipid Characteristics of African American

Individuals With Nonsense Mutations in PCSK9

Diagnosis and Treatment of FH

Diagnosis and Treatment of FH

Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

ENHANCE: Heterozygous FH

PCSK9 mAb vs Placebo on LDL-C Levels

Statin Therapy: Muscular Adverse Effects

Safety of Long-term AMG 145

Lipid-Lowering Therapy Initiation

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)